Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
08:19am, Wednesday, 11'th Mar 2026
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
10:08am, Monday, 09'th Mar 2026
BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Fisher Asset Management LLC Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN
03:58am, Saturday, 07'th Mar 2026
Fisher Asset Management LLC lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 134.2% during the undefined quarter, according to the company in its most recent filing with the SEC.
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:42pm, Wednesday, 04'th Mar 2026
BioMarin Pharmaceutical Inc. (BMRN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
06:10am, Monday, 02'nd Mar 2026
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc.
05:05am, Monday, 02'nd Mar 2026
Envestnet Asset Management Inc. trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 50.4% in the undefined quarter, according to the company in its most recent disclosure with the S
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy app
DNB Asset Management AS Acquires 154,954 Shares of BioMarin Pharmaceutical Inc. $BMRN
04:27am, Friday, 27'th Feb 2026
DNB Asset Management AS increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 13.8% in the undefined quarter, according to its most recent filing with the SEC. The fund ow
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market
12:36pm, Tuesday, 24'th Feb 2026
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
10:50am, Tuesday, 24'th Feb 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin to Participate in Four Upcoming Investor Conferences in March
09:00am, Tuesday, 24'th Feb 2026
TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 Leerink 2026 Global Healthcare Conference on Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit on Tuesday, March
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
11:14pm, Monday, 23'rd Feb 2026
BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics
09:01pm, Monday, 23'rd Feb 2026
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Str
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
08:26pm, Monday, 23'rd Feb 2026
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.92 per share a year ago.
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
04:05pm, Monday, 23'rd Feb 2026
Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® Fourth Quarter 2025 Total Revenues Increased 17% Y/Y
